CardioKinetix reports positive data of Parachute device

28 August 2012 (Last Updated August 28th, 2012 18:30)

CardioKinetix has reported positive three-year clinical data of its minimally invasive Parachute ventricular partitioning device, designed to treat patients with heart failure caused by damage to the heart muscle following a heart attack.

CardioKinetix has reported positive three-year clinical data of its minimally invasive Parachute ventricular partitioning device, designed to treat patients with heart failure caused by damage to the muscle following a heart attack.

By utilising a small catheter, the Parachute device is implanted into the left ventricle to partition the damaged muscle, separating the non-functional heart segment from the healthy functional segment, to decrease the overall volume of the left ventricle and restore its geometry and function.

The trial has enrolled 31 patients across US and Europe to demonstrate the safety and efficacy of Parachute.

The results demonstrated meaningful and sustained low clinical events in heart failure patients as well as the New York Heart Association (NYHA) class improvements were observed at one and two years and was maintained at three years post-treatment (average NYHA class of 2.6 at baseline vs 1.8 at three years, p<0.0001).

The results also showed that the rate of hospitalisation due to worsening heart failure was 29.7% at two years, and 33.2% at three years, and the low rate of cardiac death of 6.5% at two years remained unchanged at three years.

Harrington Heart & Vascular Institute Interventional Cardiovascular Centre and the Research and Innovation Centre director Dr Marco Costa said; "In the two first-in-man studies, the Parachute device demonstrated its safety and sustained improvements in symptoms, heart function, and clinical outcomes over three years, pointing to a potential historical turning point in the treatment for post-MI heart failure patients."

CardioKinetix president and CEO Maria Sainz said; "We are focused on completing our real-world European post-market surveillance trial and initiating our U.S. pivotal trial to pursue our plans to bring this therapy to patients suffering from heart failure globally."